Sarah Sinclair, Cannabis Health
New findings from the UK link medical cannabis treatment to improvements in quality of life among ADHD patients.
A new study using data from the UK Medical Cannabis Registry suggest that patients prescribed cannabis-based medicinal products (CBPMs) for attention-deficit/hyperactivity disorder (ADHD) showed improvements in sleep, anxiety and overall quality of life.
ADHD is one of the most common conditions for which medical cannabis is prescribed in the UK, closely following chronic pain and anxiety disorders.
The prevalence of neurodevelopmental conditions has also been on the rise in recent years, with 2.6 million people in the UK now diagnosed with ADHD.